Skip to content
Back to NAMS

NewAmsterdam Pharma Co N.V.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
44
Purchases
1
Sales
43
Purchase value
$226.50K
Sale value
$63.25M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Johannes Jacob Pieter KasteleinDirector · Chief Scientific Officer
4Rule 10b5-1 plan disclosed
Filed Oct 2, 2026Period of report Sep 30, 20260001193125-26-412431
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 30, 2026
Ordinary SharesF3F250,246$25.03$1.26M69,302IndirectSee footnotes
Filing footnotes · 6
  1. F1The exercise price of the option is EUR 1.16392.
  2. F2These Ordinary Shares are held by Futurum B.V. ("Futurum") through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum.
  3. F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.10 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  4. F4Includes 48,166 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
  5. F5The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
  6. F6The option was granted to and is held by Futurum through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer.
Open on SEC EDGAR
Michael H. DavidsonDirector · Chief Executive Officer
4
Filed Sep 15, 2026Period of report Sep 14, 20260001193125-26-391985
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseSep 14, 2026
Ordinary SharesF1F210,000$22.65$226.50K792,923Direct
Filing footnotes · 3
  1. F1Includes 163,352 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
  2. F2Reflects the prior transfer of 608,779 ordinary shares previously reported as indirectly beneficially owned by the Reporting Person. Such ordinary shares were previously held of record by Stichting Administratiekantoor EPNAP for the benefit of the Reporting Person.
  3. F3These Ordinary Shares are held by the Michael H. Davidson 2026 Grantor Retained Annuity Trust (the "GRAT"). The Reporting Person is the sole annuitant and trustee of the GRAT.
Open on SEC EDGAR
John W SmitherDirector
4
Filed Sep 9, 2026Period of report Sep 4, 20260001193125-26-386508
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 4, 2026
Ordinary SharesF1F2F31,600$25.32$40.51K8,760Direct
Filing footnotes · 3
  1. F1Reported transaction reflects a sale of ordinary shares to generate proceeds to satisfy the Reporting Person's tax obligations in connection with the prior vesting of restricted stock units.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.24 to $25.37 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  3. F3Includes 8,040 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
Open on SEC EDGAR
Johannes Jacob Pieter KasteleinDirector · Chief Scientific Officer
4Rule 10b5-1 plan disclosed
Filed Aug 25, 2026Period of report Aug 24, 20260001193125-26-365202
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 24, 2026
Ordinary SharesF3F2125,000$26.91$3.36M69,302IndirectSee footnotes
Filing footnotes · 6
  1. F1The exercise price of the option is EUR 1.16392.
  2. F2These Ordinary Shares are held by Futurum B.V. ("Futurum") through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum.
  3. F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.72 to $27.70 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  4. F4Includes 48,166 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
  5. F5The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
  6. F6The option was granted to and is held by Futurum through PoolCo for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer.
Open on SEC EDGAR
Louise Frederika KooijChief Accounting Officer
4Rule 10b5-1 plan disclosed
Filed Jul 22, 2026Period of report Jul 20, 20260001193125-26-312387
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 20, 2026
Ordinary SharesF2F170,200$29.96$2.10M59,153Direct
SaleJul 20, 2026
Ordinary SharesF3F131,885$31.05$990.03K27,268Direct
SaleJul 20, 2026
Ordinary SharesF4F12,915$31.71$92.43K24,353Direct
Filing footnotes · 6
  1. F1Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.57 to $30.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  3. F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.58 to $31.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  4. F4The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.58 to $31.85 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  5. F5The option was granted on May 18, 2023. 25% of the shares underlying the option vested on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
  6. F6The option was granted on January 1, 2024. 25% of the shares underlying the option vested on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Open on SEC EDGAR
Louise Frederika KooijChief Accounting Officer
4Rule 10b5-1 plan disclosed
Filed Jun 24, 2026Period of report Jun 22, 20260001193125-26-281062
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 22, 2026
Ordinary SharesF1F239,700$30.20$1.20M24,653Direct
SaleJun 22, 2026
Ordinary SharesF2300$30.73$9.22K24,353Direct
Filing footnotes · 4
  1. F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.73 to $30.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  2. F2Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
  3. F3The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
  4. F4The option was granted on May 18, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Open on SEC EDGAR
Louise Frederika KooijChief Accounting Officer
4Rule 10b5-1 plan disclosed
Filed May 27, 2026Period of report May 26, 20260001193125-26-241983
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 26, 2026
Ordinary SharesF1F265,000$35.69$2.32M24,353Direct
Filing footnotes · 4
  1. F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.12 to $36.09 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  2. F2Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
  3. F3The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 1, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date.
  4. F4The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Open on SEC EDGAR
Louis G LangeDirector
4
Filed Mar 12, 2026Period of report Mar 11, 20260001193125-26-104239
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 11, 2026
Ordinary SharesF144,173$30.41$1.34M10,806Direct
SaleMar 11, 2026
Ordinary SharesF2446$31.23$13.93K10,360Direct
Filing footnotes · 2
  1. F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.11 per share to $31.08 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.13 per share to $31.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
Open on SEC EDGAR
Johannes Jacob Pieter KasteleinDirector · Chief Scientific Officer
4Rule 10b5-1 plan disclosed
Filed Mar 9, 2026Period of report Mar 5, 20260001193125-26-099073
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 9, 2026
Ordinary SharesF5F2101,409$30.29$3.07M69,302IndirectSee footnote
SaleMar 6, 2026
Ordinary SharesF4F294,124$30.32$2.85M69,302IndirectSee footnote
SaleMar 5, 2026
Ordinary SharesF3F2104,467$30.30$3.17M69,302IndirectSee footnote
Filing footnotes · 7
  1. F1The exercise price of the option is EUR 1.16392.
  2. F2The Ordinary Shares are held by Futurum B.V. ("Futurum") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum.
  3. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 per share to $30.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  4. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 per share to $30.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  5. F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 per share to $30.80 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  6. F6The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
  7. F7The option was granted to and is held by Futurum through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer.
Open on SEC EDGAR
Louis G LangeDirector
4
Filed Mar 10, 2026Period of report Mar 6, 20260001193125-26-100798
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 6, 2026
Ordinary SharesF1F228,186$29.41$828.95K0IndirectSee footnote
Filing footnotes · 2
  1. F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.03 per share to $29.68 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  2. F2The shares are held directly by LGLange III Trust DTD10 (the "Trust") for the benefit of the Reporting Person.
Open on SEC EDGAR
Michael H. DavidsonDirector · Chief Executive Officer
4
Filed Mar 2, 2026Period of report Mar 2, 20260001193125-26-085947
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 2, 2026
Ordinary Shares443,707$33.25$14.75M174,144Direct
Filing footnotes · 2
  1. F1The exercise price of the option is EUR 1.16392.
  2. F2The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Open on SEC EDGAR
Michael H. DavidsonDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Feb 26, 2026Period of report Feb 24, 20260001193125-26-078718
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 26, 2026
Ordinary SharesF7165,408$33.63$5.56M477,783Direct
SaleFeb 26, 2026
Ordinary SharesF8F917,924$34.44$617.30K174,144Direct
SaleFeb 25, 2026
Ordinary SharesF446,517$35.11$1.63M471,595Direct
SaleFeb 25, 2026
Ordinary SharesF510,436$35.96$375.28K461,159Direct
SaleFeb 25, 2026
Ordinary SharesF61,300$36.68$47.68K459,859Direct
SaleFeb 24, 2026
Ordinary SharesF261,547$36.13$2.22M463,020Direct
SaleFeb 24, 2026
Ordinary SharesF33,161$36.46$115.25K459,859Direct
Filing footnotes · 10
  1. F1The exercise price of the option is EUR 1.16392.
  2. F10The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
  3. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.43 to $36.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  4. F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.43 to $36.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  5. F4The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.57 to $35.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  6. F5The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.57 to $36.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  7. F6The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.58 to $36.74 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  8. F7The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.34 to $34.33 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  9. F8The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.35 to $34.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  10. F9The amount reported in Column 5 reflects the transfer of 285,715 ordinary shares from the Reporting Person to the Michael H. Davidson 2026 Grantor Retained Annuity Trust (the "GRAT") on February 26, 2026, which transfer was exempt from Section 16 pursuant to Rule 16a-13 under the Securities Exchange Act of 1934. The Reporting Person is the sole annuitant and trustee of the GRAT.
Open on SEC EDGAR
Johannes Jacob Pieter KasteleinDirector · Chief Scientific Officer
4
Filed Feb 24, 2026Period of report Feb 20, 20260001193125-26-067260
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 20, 2026
Ordinary SharesF114,692$35.00$514.22K84,289Direct
SaleFeb 20, 2026
Ordinary SharesF230,789$35.46$1.09M53,500Direct
Filing footnotes · 2
  1. F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.24 to $35.23 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.24 to $35.86 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
Open on SEC EDGAR
Louise Frederika KooijChief Accounting Officer
4Rule 10b5-1 plan disclosed
Filed Jan 29, 2026Period of report Jan 27, 20260001193125-26-029526
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 28, 2026
Ordinary SharesF232,612$31.80$1.04M24,353Direct
SaleJan 27, 2026
Ordinary SharesF139,816$32.62$1.30M24,353Direct
Filing footnotes · 3
  1. F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.29 to $32.97 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.58 to $32.53 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  3. F3The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Open on SEC EDGAR
Louise Frederika KooijChief Accounting Officer
4Rule 10b5-1 plan disclosed
Filed Jan 27, 2026Period of report Jan 23, 20260001193125-26-025012
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 26, 2026
Ordinary SharesF334,091$32.77$1.12M24,662Direct
SaleJan 26, 2026
Ordinary SharesF4309$33.45$10.34K24,353Direct
SaleJan 23, 2026
Ordinary SharesF125,405$33.44$849.54K37,120Direct
SaleJan 23, 2026
Ordinary SharesF212,767$34.37$438.80K24,353Direct
Filing footnotes · 5
  1. F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.06 to $34.05 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.06 to $34.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  3. F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.40 to $33.38 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  4. F4The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.40 to $33.51 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  5. F5The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Open on SEC EDGAR
Mayur Ian SomaiyaChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Jan 22, 2026Period of report Jan 20, 20260001193125-26-019686
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 21, 2026
Ordinary SharesF1F515,422$33.25$512.78K82,744Direct
SaleJan 21, 2026
Ordinary SharesF1F624,362$33.80$823.44K58,382Direct
SaleJan 20, 2026
Ordinary SharesF1F2900$30.64$27.58K117,698Direct
SaleJan 20, 2026
Ordinary SharesF1F339,712$31.78$1.26M77,986Direct
SaleJan 20, 2026
Ordinary SharesF1F419,604$32.38$634.78K58,382Direct
Filing footnotes · 7
  1. F1This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
  2. F2These shares were sold in multiple transactions at prices ranging from $30.17 per share to $30.85 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  3. F3These shares were sold in multiple transactions at prices ranging from $31.29 per share to $32.28 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  4. F4These shares were sold in multiple transactions at prices ranging from $32.29 per share to $32.58 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  5. F5These shares were sold in multiple transactions at prices ranging from $32.48 per share to $33.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  6. F6These shares were sold in multiple transactions at prices ranging from $33.48 per share to $34.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  7. F7The option was granted on November 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Open on SEC EDGAR
Michael H. DavidsonDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Jan 9, 2026Period of report Jan 7, 20260001193125-26-009272
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 7, 2026
Ordinary SharesF1F211,582——378,859Direct
Filing footnotes · 5
  1. F1Represents pre-arranged sale of shares by the Reporting Person solely to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units (RSUs) pursuant to sell-to-cover agreement entered into with the Issuer. The sale does not represent a discretionary transaction by the Reporting Person.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.24 to $35.59 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  3. F3Represents RSUs, each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date.
  4. F4Each RSU was granted on January 7, 2026 for no consideration.
  5. F525% of the shares underlying the option will vest on Janaury 2, 2027, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Open on SEC EDGAR
Johannes Jacob Pieter KasteleinDirector · Chief Scientific Officer
4Rule 10b5-1 plan disclosed
Filed Jan 7, 2026Period of report Jan 5, 20260001193125-26-006662
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 5, 2026
Ordinary SharesF1F26,000$33.25$199.50K73,481Direct
Filing footnotes · 5
  1. F1Represents pre-arranged sale of shares by the Reporting Person solely to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units (RSUs) pursuant to sell-to-cover agreement entered into with the Issuer. The sale does not represent a discretionary transaction by the Reporting Person.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.77 to $33.58 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  3. F3Represents RSUs, each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date.
  4. F4Each RSU was granted on January 7, 2026 for no consideration.
  5. F525% of the shares underlying the option will vest on Janaury 2, 2027, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Open on SEC EDGAR
Louise Frederika KooijChief Accounting Officer
4Rule 10b5-1 plan disclosed
Filed Jan 7, 2026Period of report Jan 5, 20260001193125-26-006659
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 5, 2026
Ordinary SharesF1F22,647$33.25$88.01K12,353Direct
Filing footnotes · 5
  1. F1Represents pre-arranged sale of shares by the Reporting Person solely to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units (RSUs) pursuant to sell-to-cover agreement entered into with the Issuer. The sale does not represent a discretionary transaction by the Reporting Person.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.77 to $33.58 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  3. F3Represents RSUs, each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date.
  4. F4Each RSU was granted on January 7, 2026 for no consideration.
  5. F525% of the shares underlying the option will vest on Janaury 2, 2027, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Open on SEC EDGAR
Mayur Ian SomaiyaChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Jan 7, 2026Period of report Jan 5, 20260001193125-26-006658
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 5, 2026
Ordinary SharesF1F25,118$33.25$170.17K32,882Direct
Filing footnotes · 5
  1. F1Represents pre-arranged sale of shares by the Reporting Person solely to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units (RSUs) pursuant to sell-to-cover agreement entered into with the Issuer. The sale does not represent a discretionary transaction by the Reporting Person.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.77 to $33.58 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  3. F3Represents RSUs, each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date.
  4. F4Each RSU was granted on January 7, 2026 for no consideration.
  5. F525% of the shares underlying the option will vest on Janaury 2, 2027, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Open on SEC EDGAR
Louise Frederika KooijChief Accounting Officer
4Rule 10b5-1 plan disclosed
Filed Dec 29, 2025Period of report Dec 23, 20250001193125-25-335513
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 26, 2025
Ordinary SharesF343,872$35.30$1.55M15,000Direct
SaleDec 24, 2025
Ordinary SharesF226,011$35.68$928.07K15,000Direct
SaleDec 23, 2025
Ordinary SharesF175,117$36.21$2.72M15,000Direct
Filing footnotes · 5
  1. F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.88 to $36.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.24 to $36.09 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  3. F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.85 to $35.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  4. F4The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 1, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date.
  5. F5The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.